BioSpace News Archive

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7th at 9:00 am ET.

Novartis presents positive primary endpoint data from the pivotal Phase III NATALEE trial at the 2023 American Society of Clinical Oncology Annual Meeting.

Savara Inc. announced that its management team will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2023 at 10:30 am ET/7:30 am PT.

UroGen Pharma Ltd. today announced that it will present at the following investor conferences in June.

MEI Pharma, Inc. today announced that, in connection with the Company’s previously announced succession plan, Daniel P. Gold, Ph.D’s tenure as the president and chief executive officer of MEI will end on June 2, 2023 and the Company’s board of directors has appointed David M. Urso as his successor.

Agilent Technologies Inc. (NYSE: A) today announced new mass spectrometry solutions on show at the 71st ASMS Conference on Mass Spectrometry and Allied Topics, being held June 4 - 8 in Houston, Texas.

Biological Dynamics, a leader in exosome-isolation technology for early disease detection, will present a poster featuring its ExoLuminate study design, currently enrolling, at The American Society of Clinical Oncology (ASCO), June 2-6, 2023 in Chicago, IL.

Providence Therapeutics Holdings Inc. (“Providence”), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, today announced its mRNA drug discovery partnership with University Health Network (UHN), ranked first on a list of Canada’s top 40 research hospitals by Research Infosource Inc. and within one of the world’s top 5 hospitals for the fourth year in a row, as reported by Newsweek.

SciSparc Ltd. announced positive topline results from its investigator-initiated Phase IIa trial at the Sophie & Abraham Stuchynski Israeli Alzheimer’s Medical Center, which suggest that the Company’s proprietary SCI-110 is safe and tolerable while significantly improving agitation symptoms over time in elderly population with Alzheimer disease and agitation.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab) today announced a poster presentation at the 2023 European Congress of Rheumatology, hosted by the European Alliance of Association for Rheumatology (EULAR) and held in Milan, Italy May 31–June 3, 2023.